Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients

Table 3 Incidence of CMV disease and asymptomatic CMV infection in D+/R− transplants according to era after HTx

Era	Prophylaxis	CMV disease, n (%)	Asymptomatic CMV infection, n (%)	No CMV, n (%)
1988–1991 (n = 18)	No	12 (67)	5 (28)	1 (5)
1992–1997 (n = 17)	Pre-emptive^a	13 (76)	3 (18)	1 (6)
1998–2000 (n = 11)	Universal^b	5 (46)	3 (27)	3 (27)
Total (n = 46)		30 (65)	11 (24)	5 (11)

^aPre-emptive treatment, monitoring with qualitative CMV PCR once weekly or two weeks apart for the first three months post-transplantation ^b1,000 mg of oral ganciclovir tid for 14 weeks

ISSN: 1471-2334